Xenon Pharmaceuticals Inc (XENE.OQ)
20 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|71||Chairman of the Board|
|39||2015||Chief Financial Officer, Chief Operating Officer|
|2016||Senior Vice President - Drug Discovery|
|54||2012||Senior Vice President of Business and Corporate Development|
|66||2008||Vice President - Biology|
- BRIEF-Xenon Advances Second Proprietary Epilepsy Product Into Clinic With Initiation Of Xen901 Phase 1 Clinical Trial
- BRIEF-Xenon Pharmaceuticals Expects To Have Ongoing XEN1101 Phase 1 Clinical Trial Completed By Mid-Year
- BRIEF-Xenon Pharma Says Entered Into Loan And Security Agreement With Silicon Valley Bank
- BRIEF-Xenon Pharmaceuticals reports Q3 loss per share $0.43
- BRIEF-Xenon Pharma announces initiation of XEN1101 phase 1 clinical trial